Tag: Drug Development

Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the ...

Australian psychedelic medicine company Emyria Limited (ASX: EMD) has been selected by the US Food and Drug Administration (FDA) to ...

For decades, psychedelic medicine sat on the margins of psychiatry, constrained by international drug controls, political controversy and the legacy ...

The UK’s psychedelic sector is moving into a more commercially significant phase, with late-stage clinical programmes, pharmaceutical investment and changes ...

Emyria is building a second business behind its growing mental health operation: a drug discovery and development programme focused on ...

For much of the past five years, the psychedelic medicine sector has been driven by a relatively straightforward investment thesis. ...